JMP Securities Downgrades Carbylan Therapeutics (CBYL) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Carbylan Therapeutics (CBYL) Announces Suspension of Further Hydros-TA Development; Exploring Strategic Transaction
April 15, 2016 7:31 AM EDTCarbylan Therapeutics (Nasdaq: CBYL) announced that it has suspended further clinical development of Hydros-TA and that it is actively pursuing a strategic transaction, including a merger or acquisition of the company. As previously announced, Carbylan has engaged Wedbush PacGrow to act as its... More
Carbylan Therapeutics (CBYL) trading halted with news pending
April 15, 2016 7:30 AM EDTCarbylan Therapeutics (NASDAQ: CBYL) trading halted with news pending.
... More